* Indications:
Hepatic Encephalopathy:
IDIBACT 550 mg is indicated for reduction in the risk of recurrence of overt hepatic encephalopathy (HE) in patients (>/= 18 years of age) with advanced liver disease.
Differences in treatment effect in patients using lactulose concomitantly with rifaximin couldn’t be assessed.
There is increased systemic exposure in patients with more severe hepatic dysfunction.
المراجعات
لا توجد مراجعات بعد.